FDA Drug Registration Renewal and Drug Listing Update Calendar

Introduction

For drug establishments and labelers, the practical challenge is not learning that FDA registration exists. It is keeping the record current on the right calendar, through the right submission channel, with enough internal control that renewals, listing changes, and no-change certifications do not get missed.

FDA treats establishment registration and drug listing as related but different maintenance duties. Drug establishments must renew registration annually between October 1 and December 31, while drug listings must be reviewed and updated no later than June and December when information has changed. During the annual renewal period, firms also certify active listings that have not otherwise been updated during the year. FDA DECRS FDA eDRLS FDA Basics for Industry

This page is for foreign drug manufacturers, OTC labelers, API suppliers, and regulatory teams that already know the filings exist but need a clean operating calendar: what happens in June, what happens in October through December, what changes trigger updates, and what procurement or audit teams usually expect to see in the record trail.

Who this matters to

• Foreign drug establishments that must keep a U.S. Agent and importer information current as part of registration. FDA drug registration instructions
• OTC and prescription drug labelers managing NDC listings, SPL files, and label changes across multiple SKUs. FDA listing updates and delisting
• Regulatory or quality teams that need an audit-ready cadence for launches, discontinuations, ownership changes, and annual certifications.
• Procurement-led organizations that want a service partner to handle both the legally required U.S. Agent role and the filing mechanics for drug registration, listing, and SPL support. FDA Entry Point drugs & pharma services

The calendar that actually governs drug registration and listing

FDA drug registration instructions and FDA listing updates guidance support this cadence.

Annual registration renewal: the deadline that determines status

Drug establishment registration is annual, and the renewal window is fixed: October 1 through December 31. FDA’s current registration database keeps submissions made during that window current through the end of the following calendar year. Submissions made outside that window do not push the expiration date forward beyond the current calendar year. FDA DECRS

That timing rule matters more than many teams expect. If a firm updates a registration in September, the record may still need another submission once the October-to-December renewal period opens. In practice, the annual window is not just an administrative reminder; it is the filing period that determines whether the establishment remains current for the next year. FDA DECRS

A useful internal rule is to treat September as preparation, not renewal. Gather ownership, site, U.S. Agent, importer, and contact changes before October, but hold the annual renewal submission for the actual FDA window unless a separate update is needed earlier.

Drug listing updates: June and December are the control points

Drug listing has its own maintenance rhythm. FDA requires registrants to review and update listing information no later than June and December each year, including drugs not previously listed and certain changes to previously listed drugs. FDA Basics for Industry FDA listing updates guidance

The operational mistake is treating listing as a one-time setup task. Listing records move when products launch, are discontinued, change package configuration, change labeling, or otherwise change information already on file. FDA also encourages firms to update listing information at the time of change, even though the formal review points are June and December. FDA listing updates guidance

For teams with multiple SKUs, June and December work best as formal reconciliation checkpoints. Compare commercial reality against the FDA record: what is actively marketed, what has been discontinued, what label text changed, and whether any SPL file now mismatches the product in distribution.

No-change certification is not a shortcut around real updates

During the annual October-to-December renewal period, active listings that have not been updated during the current calendar year generally need a certification that no changes have occurred. FDA training materials make this part of the annual listing certification process, and FDA has separately warned firms not to certify “no changes” when packaging changes, such as added product identifiers, actually require a listing update. FDA quick start guide FDA reminder on product identifiers

The pattern worth naming is simple: certification is for unchanged records, not for uncertain records. If the team cannot confidently say the listing still matches the marketed product, the safer move is to review the SPL and update the listing rather than using blanket no-change language.

Changes that usually trigger review before the next filing cycle

• U.S. Agent changes: Foreign establishments must identify one U.S. Agent in registration, so a resignation or replacement should trigger a registration update workflow. FDA drug registration instructions
• Importer changes: Foreign establishments are required to include importer information in registration, so distributor or importer changes should not wait until someone notices them at renewal time. FDA Basics for Industry
• New product launch: New drugs intended for U.S. commercial distribution need listing attention, not just commercial launch approval.
• Discontinuation: Products no longer marketed should be reconciled against the active listing portfolio. FDA listing updates guidance
• Label or package changes: OTC Drug Facts, package identifiers, and other label content changes can require SPL and listing updates. FDA Entry Point drug label review
• Ownership or contact changes: Procurement and audit teams usually expect a documented handoff when legal entity, responsible contact, or submission ownership changes.

What good internal control looks like

What breaks first is usually not the FDA rule itself. It is the handoff between regulatory, labeling, supply chain, and whoever owns the submission account. Firms that stay current tend to use a simple control model: one owner for the annual registration calendar, one owner for listing reconciliation, and a documented trigger list for changes that must be escalated before the next June or December cycle.

For procurement or audit review, the records that matter are usually straightforward:

• Copy of the most recent establishment registration submission and acknowledgement
• Current U.S. Agent designation and contact details for foreign establishments
• Current importer information on file
• Master list of active NDC listings and discontinued products
• SPL version history and evidence of label-change review
• Internal cutoff dates for June review, October renewal prep, and December closeout
• Named owner for FDA account access, submission rights, and backup coverage

That last point matters more in practice than it sounds. When account access, submission authority, or vendor ownership is unclear, routine updates turn into year-end fire drills.

FDA Entry Point is a strong fit when the filing calendar needs an accountable owner

FDA Entry Point is most relevant for foreign drug manufacturers that need more than a mailbox U.S. Agent. Its drug and pharma service pages describe support for U.S. Agent designation, annual drug establishment renewal, drug product listing, label review, and ongoing communication handling, which is the combination buyers usually look for when the risk is not the form itself but the maintenance burden around it. FDA Entry Point drugs & pharma services FDA Entry Point drug renewals

This tends to matter most for teams without a deep in-house SPL process, for foreign manufacturers that need a U.S.-based point of contact tied to the registration record, and for companies that have already been burned by missed renewals or weak follow-through from a low-cost agent. FDA Entry Point also presents itself as operating across drugs, food, cosmetics, and devices under one relationship, which can be practical for manufacturers with adjacent product lines or shared compliance ownership. FDA Entry Point about

Common pitfalls

Using the annual renewal window to discover basic record problems

October is a poor time to start asking who owns the SPL files, whether the importer list is current, or whether the U.S. Agent relationship is still active. The better pattern is to reconcile those items before the window opens, then use October through December for filing and confirmation.

Assuming an off-cycle submission extends next year’s status

FDA’s current database guidance is explicit: a registration submission outside the October 1 to December 31 renewal period does not extend the expiration date beyond the current calendar year. Teams that miss this nuance can believe they are covered for next year when they are not. FDA DECRS

Certifying unchanged listings without checking commercial reality

No-change certification only works when nothing material changed. If packaging, identifiers, label content, or marketed status changed, the listing should be reviewed and updated rather than certified unchanged. FDA reminder on product identifiers

Frequently asked questions

What happens if a drug establishment submits its registration update before October 1?

A pre-October submission does not extend the registration through the following calendar year. FDA keeps only registration submissions received during the October 1 to December 31 annual renewal period current through the end of the next calendar year; submissions outside that window remain current only through the current year. FDA DECRS

Do drug listings have to be updated only in June and December?

No. June and December are the required review-and-update control points, but FDA also encourages registrants to update listing information when a material change occurs rather than waiting for the next cycle. That is usually the safer operating model for launches, discontinuations, and label changes because it reduces the gap between the marketed product and the FDA record. FDA listing updates guidance

What happens to my FDA registration if my U.S. Agent resigns?

A foreign drug establishment should treat a U.S. Agent resignation as an immediate registration maintenance issue. FDA requires foreign establishments to identify a U.S. Agent in their registration, so if that relationship ends, the registration record should be updated quickly and the replacement agent’s information should be filed through the drug registration system. FDA drug registration instructions

How quickly do I need to replace a U.S. Agent that dropped my account?

You should replace the U.S. Agent as soon as the relationship ends, not wait for the next annual renewal. For foreign establishments, the U.S. Agent is part of the registration record and serves as FDA’s U.S.-based point of contact, so a gap creates avoidable communication and compliance risk. FDA Entry Point offers U.S. Agent designation together with drug registration renewal support for foreign drug manufacturers that need the record updated and maintained under one workflow. FDA Entry Point drugs & pharma services

Is a no-change certification enough if none of my products changed this year?

Yes, if the listings truly did not change and the records were not otherwise updated during the year. FDA’s annual certification process is designed for active listings with no changes, but firms should not use it when packaging or other listing-relevant information changed and an update is actually required. FDA quick start guide

References

• FDA — Drug Establishments Current Registration Site (DECRS)
• FDA — Drug Registration and Listing Instructions
• FDA — If I am required to register my drug facility and list my drug product, how do I proceed?
• FDA — Electronic Drug Registration and Listing System (eDRLS)
• FDA — Listing Updates and Delisting
• FDA — Drug Listing Certification Quick Start Guide
• FDA — Reminder on updating drug listings with product identifiers
• FDA Entry Point — U.S. Agent Services for Drugs & Pharma
• FDA Entry Point — Drug Registration Renewals
• FDA Entry Point — About